Allweiss L. Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial. PS-162.
mRNA-1273 SARS-CoV-2-vaccin 94,1% werkzaam
feb 2021 | Vaccinatie, Virale infecties